Aerocrine/Stallergenes sign exclusive NiOx Mino distribution pact

Aerocrine and Stallergenes have signed an exclusive long-term distribution agreement for Aerocrine's airway inflammation monitor and test kit. The agreement will initially cover France, Italy, Poland, Turkey and the Middle East and could be extended to additional countries.

The agreement, which comes into effect on 1st September 2012, gives Stallergenes exclusive rights for the marketing, sales and distribution of Aerocrine's instrument NiOx Mino and test kits, used for diagnosing and monitoring patients with asthma. The existing distribution agreement of Aerocrine with Thermo Fisher Scientific/Phadia, which covers France and Italy, will be terminated on the effective date of this new agreement.

Aerocrine offers exhaled nitric oxide (NO) monitoring devices for research and clinical applications. The company's hand-held device is intended for routine measurements, where it can be used to improve the management of asthma and other inflammatory airway conditions in both specialist and primary care clinics. NiOx Mino reportedly offers added advantages for patient care including detecting of eosinophilic airway inflammation, determining the likelihood of corticosteroid responsiveness, monitoring of airway inflammation to determine the potential need for corticosteroid, and unmasking of otherwise unsuspected non-adherence to corticosteroid therapy.

This article is tagged to:
Sector: Medical Devices
Geography: France, France, Sweden

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.